# Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

> **NCT02240030** · PHASE3 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 351 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** CVT-301 Low Dose
- **DRUG:** CVT-301 High Dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02240030
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2019-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02240030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02240030, "Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02240030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*